Posted by Michael Wonder on 28 Jun 2025
Biocon Biologics receives Health Canada approval for Yesafili (aflibercept); first global launch scheduled for July 2025
27 June 2025 - Biocon Biologics is pleased to announce that Health Canada has granted a Notice of Compliance for Yesafili (aflibercept), a biosimilar to Eylea (aflibercept) injection, in vial and pre-filled syringe presentations, 2 mg/0.05 mL on 26 June 2025.
This approval paves the way for the launch of Yesafili in Canada, scheduled for 4 July 2025.
